

**International Symposium on
Paget's Disease
17-18 July 2003**

preceded by

**Advances in the Molecular Pharmacology and
Therapeutics of Bone Disease
14-16 July 2003**

**St Catherine's College
Oxford, UK**

Programme and Abstracts

**Organised by the
National Association for the Relief of Pagets Disease
in association with the
Paget Foundation**

www.paget.org.uk
www.paget.org

Scientific Committee:

Chairman: Graham Russell (Oxford, UK)
Michael Davie (Oswestry, UK)
Michael Davies (Manchester, UK)
Roger Francis (Newcastle-upon-Tyne, UK)
David Hosking (Nottingham, UK)
Stuart Ralston (Aberdeen, UK)

Major Sponsors:

Aventis/Procter & Gamble – the Alliance for Better Bone Health
Novartis Pharma

Other Supporters:

Amgen Inc
Eli Lilly and Company
F Hoffmann-La Roche Ltd and GlaxoSmithKline Pharmaceuticals
Servier

(List as at April 2003)

Contact for further information:

Janet Crompton
Conference Organiser
The Old White Hart
North Nibley
Dursley
Glos GL11 6DS
UK

Tel + 44 (0)1453 549929
Fax + 44 (0)1453 548919
Email janet@janet-crompton.com

Advances in the Molecular Pharmacology and Therapeutics of Bone Diseases

14-16 July 2003, Oxford, UK

Organised by the University of Oxford

Institute of Musculoskeletal Sciences

Monday 14 July

11:30 REGISTRATION STARTS

13:00 LUNCH (13.00-14.00)

Chairs: Sevgi Rodan (West Point PA, USA)/Graham Russell (Oxford, UK)

Recent advances in osteoclast biology

14:00 **Jack Martin** (Melbourne, Australia): Osteoclast development and regulatory mechanisms

Recent advances in osteoblast biology

14:40 **Gideon Rodan** (West Point PA, USA): Recent advances in osteoblast biology

15:20 TEA

Osteoporosis

Chairs: Juliet Compston (Cambridge, UK)/John Wass (Oxford, UK)

15:40 **Steven Cummings** (San Francisco CA, USA): Osteoporosis: Lessons from epidemiology

16:20 **Matt Brown** (Oxford, UK): Genetics of osteoporosis

17:00 **Richard Eastell** (Sheffield, UK): Current therapy and evaluation of treatment

17:40 Close

19:00 RECEPTION AND DINNER

Tuesday 15 July

07:45 BREAKFAST

The RANK/RANK-ligand/OPG osteoprotegerin system

Chairs: Greg Mundy (San Antonio TX, USA)/Ian Reid (Auckland, New Zealand)

08:30 **Bill Dougall** (Thousand Oaks CA, USA): The biology of the RANK/RANK-Ligand/OPG osteoprotegerin system

09:10 **Peter Croucher** (Oxford, UK): Role in oncology and myeloma

09:50 COFFEE

The mevalonate pathway

Chairs: Hal Ebetino (Cincinnati OH, USA)/Jonathan Green (Basle, Switzerland)

10:20 **Mike Rogers** (Aberdeen, UK): Molecular mechanisms of action of bisphosphonates

10:50 **Al Reszka** (West Point PA, USA): Signalling pathways in osteoclasts

11:20 **Ross Garrett** (San Antonio TX, USA): Statins as bone anabolics

12:00 **Eric Niesor** (Geneva, Switzerland): Apomine and BP esters

12:45 LUNCH (12.45-13.30)

Bone oncology

Chairs: Nick Athanasou (Oxford, UK)/Jack Martin (Melbourne, Australia)

13:30 **Rob Coleman** (Sheffield, UK): Clinical concepts and current therapies

14:10 **Greg Mundy** (San Antonio TX, USA): Mechanisms, mediators and models

Steroid receptors and tissue specificity: Oestrogens and SERMs

Chairs: Henry Bryant (Indianapolis IN, USA)/Jonathan Tobias (Bristol, UK)

14:50 **David Thompson** (Groton CT, USA): Pharmacology of SERMs

15:30 TEA

Steroid receptors and tissue specificity: Glucocorticoids

Chairs: Stephen Krane (Boston MA, USA)/Ed Nemeth (Toronto, Canada)

16:00 **Rod Flower** (London, UK): Pharmacological approaches to glucocorticoid receptors

Regulatory mechanisms in calcium metabolism

16:40 **Raj Thakker** (Oxford, UK): Lessons from genetic disorders

17:20 Close

19:00 DINNER

Wednesday 16 July

07:45 BREAKFAST

Hot topics in bone pharmacology

Chairs: Rod Flower (London, UK)/Gideon Rodan (West Point PA, USA)

08:30 **Matt Gillespie** (Melbourne, Australia): The LPR5/WNT signalling pathway

09:10 **Mark Nuttall** (King of Prussia PA, USA): Drug discovery: anabolics and current opportunities

09:40 **Ed Nemeth** (Toronto, Canada): Pharmacology of the calcium-sensing receptor and drug development

10:20 COFFEE

Bone anabolics: Parathyroid hormone

Chairs: Peter Ebeling (Oxford, UK)/Jonathan Reeve (Cambridge, UK)

10:45 **Gary Krishnan** (Indianapolis IN, USA): Understanding the basis for anabolic actions

11:15 **Donato Agnusdei** (Florence, Italy): Clinical results

11:45 **David Dempster** (New York NY, USA): Bone histomorphometry

New drugs: Strontium

12:15 **Pierre Marie** (Paris, France): Strontium and bone

12:45 LUNCH (12.45-13.30)

Nutriceuticals

Chairs: Steven Cummings (San Francisco CA, USA)/Richard Eastell (Sheffield, UK)

13:30 **Roman Mühlbauer** (Berne, Switzerland): Plants and terpenoids

Metalloproteinases

14:10 **Steve Krane** (Boston MA, USA): Metalloproteinases and bone

14:50 TEA

Tissue engineering and gene therapy

Chairs: Zhan Feng Cui (Oxford, UK)/Jim Triffitt (Oxford, UK)

15:20 **Anthony Hollander** (Bristol, UK): Cartilage engineering

16:00 **Thomas Einhorn** (Boston MA, USA): Bone engineering

16:40 Close

19:00 DINNER

INTERNATIONAL SYMPOSIUM ON PAGET'S DISEASE, 17-18 JULY 2003		
Thursday 17 July 2003	Friday 18 July 2003	Saturday 19 July 2003
09.00-11.18 Epidemiology	09.00-10.40 Diagnosis and assessment	Patients' Day
09.00 Epidemiology: US perspective Bob Tiegs (Rochester MN, USA)	09.00 Advances in imaging techniques Ignac Fogelman (London, UK)	
09.30 Epidemiology: review Tim Cundy (Auckland, New Zealand)	09.20 Prediction and assessment of response: biochemical assessment Bill Fraser (Liverpool, UK)	
10.00 Epidemiology of clinical complications Cyrus Cooper (Southampton, UK)	09.40 MR/CT methods Rick Whitehouse (Manchester, UK)	
10.30 Orals	10.00 Orals	
11.18-11.45 Coffee	10.40-11.00 Coffee	
11.45-12.45 Slow virus infections and Paget's disease	11.00-12.40 Complications	
11.45 Paramyxoviruses and Paget's disease Bert Rima (Belfast, UK)	11.00 Rheumatological complications Phil Helliwell (Leeds, UK)	
12.15 How might viruses cause Paget's disease? David Roodman (Pittsburgh PA, USA)	11.20 Hearing Richard Ramsden (Manchester, UK)	
	11.40 Orthopaedic complications Jimmy Hutchison (Aberdeen, UK)	
	12.00 Orals	
12.45-14.00 Lunch and posters	12.40-14.00 Lunch and posters	

Thursday 17 July 2003 pm	Friday 18 July 2003 pm	Saturday 19 July 2003
14.00-15.26 Genetics	14.00-17.15 Treatment	Patients' day continued
14.00 Overview of Paget's genetics Wim Van Hul (Antwerp, Belgium)	14.00 Pre-clinical evaluation of bisphosphonates Jonathan Green (Basle, Switzerland)	
14.30 Orals		
15.26 Tea	14.30 Comparison of UK and US practice and guidelines Peter Selby (Manchester, UK)/ Ethel Siris (New York NY, USA)	
16.00 Familial expansile osteolysis and RANK Anne Hughes (Belfast, UK)		
16.30 Juvenile Paget's – genotype/phenotype relationships Michael Whyte (St Louis MO, USA)	15.10 Orals	
	15.48 Tea	
17.00 Orals (to 17.32)	16.15 Treatment controversies	
17.45 Keynote lecture Stephen Krane (Boston MA, USA)	17.30 Keynote lecture Sir Julian Paget	
19.30 <i>Reception</i>	19.00 <i>Dinner</i>	
20.00 <i>Conference Dinner</i>		

Thursday 17 July

08:00 BREAKFAST

09:00-11:18 Epidemiology

Chairs: Steven Cummings

09:00 IS1 EPIDEMIOLOGY: US PERSPECTIVE
Bob Tiegs (Rochester MN, USA)

09:30 IS2 EPIDEMIOLOGY: REVIEW
Tim Cundy (Auckland, New Zealand)

10:00 IS3 EPIDEMIOLOGY OF CLINICAL COMPLICATIONS
Cyrus Cooper (Southampton, UK)

10:30 Oral communications

Chairs: Steven Cummings/David Hosking

10:30 1 PAGET'S CASES IN THE SE LONDON COMMUNITY IDENTIFIED BY ISOLATED RAISED TOTAL SERUM ALKALINE PHOSPHATASE
C Moniz, R Chandra, T Mangion, B Bowden. Clinical Biochemistry, Kings College Hospital, London, UK

10:38 2 CLINICAL ASPECTS AND COMPLICATIONS OF PAGET'S DISEASE:A REVIEW OF 100 PATIENTS IN HUNGARY
J Donáth, P Gergely Jr, G Poór. National Institute of Rheumatology and Physiotherapy, Budapest, Hungary

10:46 3 PREVALENCE AND CLINICAL FEATURES OF PAGET'S DISEASE OF BONE IN JAPAN
J Hashimoto, I Ohno, K Nakatsuka, N Yoshimura, K Yoh, M Fukunaga, S Takata, M Terada, H Yabe, S Abe, M Zamma, H Yoshikawa. The Committee on clinical guideline of diagnosis and treatment of Paget's disease of bone in Japan

10:54 4 CHARACTERISTICS AND FAMILIAL AGGREGATION OF PAGET'S DISEASE OF BONE IN ITALY
D Merlotti, B Galli, F Cipolli, F Iovine, N Dal Canto, A Spinola, L Gennari, R Valenti, G Martini, R Nuti. Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Italy

- 11:02 5 RADIOLOGICAL PREVALENCE OF PELVIC PAGET'S DISEASE IN ITALY
L Gennari^[1], S Geraci^[1], D Merlotti^[1], N Giordano^[1], C Baldi^[2], S Capoccia^[2], A Amendola^[1], G Martini^[1], R Nuti^[1]. ^[1]Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry; ^[2]Department of Radiology, University of Siena, Italy
- 11:10 6 CHANGES IN FREQUENCY OF MONOSTOTIC DISEASE AND AGE AT PRESENTATION OF PAGET'S DISEASE OF BONE OVER 20YEARS
M W J Davie^[1], M J Haddaway^[2], I W McCall^[2]. ^[1]Charles Salt Centre for Bone Metabolism; ^[2]Department of Diagnostic Imaging, Robert Jones & Agnes Hunt Orthopaedic Hospital, Oswestry, Shropshire, UK.
- 11:18 COFFEE AND POSTERS
- 11:45-12:45 Slow virus infections and Paget's disease
Chairs: Nick Athanasou/Ian Reid
- 11:45 IS4 PARAMYXOVIRUSES AND PAGET'S DISEASE
Bert Rima (Belfast, UK)
- 12:15 IS5 HOW MIGHT VIRUSES CAUSE PAGET'S DISEASE?
David Roodman (Pittsburgh PA, USA)
- 12:45 LUNCH
- 13:30 Attended posters (odd-numbered posters, 1, 3, 5 etc)
- 14:00-15:26 Genetics
Chairs: Jacques Brown/Stuart Ralston
- 14:00 IS6 OVERVIEW OF PAGET'S GENETICS
Wim Van Hul (Antwerp, Belgium)
- 14:30 Oral communications
- 14:30 7 FINE MAPPING OF PDB5 & PDB6 LOCI IN FAMILIAL PAGET'S DISEASE OF BONE
L J Hocking, S H Ralston. Department of Medicine and Therapeutics, University of Aberdeen, UK
- 14:38 8 GENETIC HETEROGENEITY OF PAGET DISEASE OF BONE IN FRENCH-CANADIAN FAMILIES
J Morissette, N Laurin, S Auger, V Raymond, J P Brown. Centre de recherche du CHUL, Université Laval, Québec, P.Q., Canada

- 14:46 9 LARGE PHENOTYPIC VARIABILITY OF PAGET DISEASE OF BONE
CAUSED BY THE P392L SEQUESTOSOME1/P62 MUTATION
N Laurin, J Morissette, V Raymond, J P Brown. Centre de recherche du
CHUL, Université Laval, Québec, P.Q., Canada
- 14:54 10 STRUCTURE/FUNCTION ANALYSIS OF THE UBIQUITIN-ASSOCIATED
DOMAIN OF THE P62/SQSTM1 PROTEIN
J R Cavey^[1], B Ciani^[2], M S Searle^[2], P W Sheppard^[3], S H Ralston^[4], R
Layfield^[1]. ^[1]School of Biomedical Sciences; ^[2]Department of Chemistry,
University of Nottingham, UK; ^[3]Affiniti Research Products Ltd, Palatine
House, Matford Court, Exeter, UK; ^[4]Department of Medicine and
Therapeutics, University of Aberdeen, UK
- 15:02 11 EVIDENCE OF AN ALLELIC ASSOCIATION BETWEEN SINGLE
NUCLEOTIDE POLYMORPHISMS IN EXON6 OF SQSTM1/P62 AND
PAGET'S DISEASE OF BONE.
G J A Lucas, L J Hocking, A Daroszewska, S H Ralston. University of
Aberdeen, UK.
- 15:10 12 MUTATIONS IN THE SEQUESTOSOME 1 GENE ARE NOT COMMON IN
ISOLATED BELGIAN PATIENTS WITH PAGET'S DISEASE.
G Beyens^[1], E Van Hul^[1], E Cleiren^[1], J P Devogelaer^[2], F
Vanhoenacker^[3], L De Clerck^[3], J Van Offel^[3], L Verbruggen^[4], W Van
Hul^[1]. ^[1]Department of Medical Genetics, University of Antwerp,
Belgium; ^[2]University Hospitals Saint-Luc, Brussels, Belgium; ^[3]
University hospital of Antwerp, Belgium; ^[4]University Hospital of
Brussels, Belgium
- 15:18 13 RECURRENT SQSTM1 GENE MUTATION AT CODON 392 IN PAGET'S
DISEASE OF BONE
L Gennari, V De Paola, A Calabrò, D Merlotti, G Martini, R Valenti, S
Salvadori, R Nuti. Department of Internal Medicine, Endocrine-
Metabolic Sciences and Biochemistry, University of Siena, Italy
- 15:26 TEA

Chairs: Stephen Krane/Jack Martin
- 16:00 IS7 FAMILIAL EXPANSILE OSTEOLYSIS AND RANK
Anne Hughes (Belfast, UK)
- 16:30 IS8 JUVENILE PAGET'S – GENOTYPE/PHENOTYPE RELATIONSHIPS
Michael Whyte (St Louis MO, USA)

7:00 Oral communications

Chairs: Stephen Krane/Jack Martin

- 17:00 14 PHENOTYPIC CHARACTERISATION OF EARLY ONSET PAGETS DISEASE OF BONE CAUSED BY A 27BP DUPLICATION IN THE TNFRSF11A GENE
K Nakatsuka^[1], Y Nishizawa^[1], S H Ralston^[2], ^[1]Osaka City University, Osaka, Japan; ^[2]University of Aberdeen, UK
- 17:08 15 SUSCEPTIBILITY TO PAGET'S DISEASE OF BONE IS INFLUENCED BY OSTEOPROTEGERIN POLYMORPHISM
A Daroszevska^[1], L J Hocking^[1], F E A McGuigan^[1], B Langdahl^[2], M D Stone^[3], W D Fraser^[4], S H Ralston^[1]. ^[1]Department of Medicine and Therapeutics, University of Aberdeen, UK; ^[2]Department of Endocrinology, Aarhus Amtssygehus, Denmark; ^[3]University of Wales College of Medicine, Cardiff, UK; ^[4]Department of Clinical Chemistry, University of Liverpool, UK
- 17:16 16 PAGETIC BONE STROMAL CELLS EXPRESS RANKL AND SUPPORT OSTEOCLAST FORMATION FROM CIRCULATING PRECURSORS
I Itonaga, A Sabokbar, SG Sun, NA Athanasou. Department of Pathology, Nuffield Department of Orthopaedic Surgery, Nuffield Orthopaedic Centre, University of Oxford, Oxford OX3 7LD, UK
- 17:24 17 GENE EXPRESSION IN THE PAGETIC OSTEOBLAST
U Bava^[1], D Naot^[1], K E Callon^[1], R P Pitto^[2], S A McCowan^[3], T Cundy^[1], I R Reid^[1], J Cornish^[1]. ^[1]Department of Medicine; ^[2]Department of Surgery; ^[3]Department of Orthopaedics, Auckland Hospital, New Zealand
- 17:45 Keynote lecture
- Chairs: Graham Russell/Roger Smith
- PAGET'S DISEASE: WHAT HAVE WE LEARNT OVER THE LAST 30 YEARS?
Stephen Krane (Boston MA, USA)
- 18:30 Close
- 19:30 RECEPTION
- 20:00 CONFERENCE DINNER

Friday 18 July

08:00 BREAKFAST

09:00-10:40 Diagnosis and assessment

Chairs: Roger Francis/Paul Miller

09:00 IS9 THE BONE SCAN IN PAGET'S DISEASE
Ignac Fogelman (London, UK)

09:20 IS10 PREDICTION AND ASSESSMENT OF RESPONSE: BIOCHEMICAL
ASSESSMENT
Bill Fraser (Liverpool, UK)

09:40 IS11 MR/CT IMAGING OF PAGET'S DISEASE OF BONE
Rick Whitehouse (Manchester, UK)

10:00 Oral communications

Chairs: Roger Francis/Paul Miller

10:00 18 18F-FLUORIDE POSITRON EMISSION TOMOGRAPHY: PRELIMINARY
ASSESSMENT OF THERAPY IN PAGET'S DISEASE OF BONE
A T Nzeusseu^[1], M Lonneux^[2], G Depresseux^[1], J Installe^[2], J P
Devogelaer^[1]. Departments of ^[1]Rheumatology; ^[2]Nuclear Medicine, St-
Luc University Hospital, Université Catholique de Louvain, B-1200
Brussels, Belgium

10:08 19 COMPARATIVE RESPONSES OF 7 BONE TURNOVER MARKERS TO
IBANDRONATE THERAPY IN PAGET'S DISEASE
I R Reid^[1], J S Davidson^[2], D Wattie^[1], F Wu^[1], J Lucas^[1], G D
Gamble^[1], T Cundy^[1]. ^[1]Department of Medicine, University of
Auckland, New Zealand; ^[2]Labplus, Auckland Hospital, New Zealand

10:16 20 THE STABILITY OF RANKL AND OPG IN HUMAN SERUM
B Y Y Chan^[1], K A Buckley^[2], B H Durham^[1], J Dutton^[1], J A
Gallagher^[2], W D Fraser^[1]. ^[1]Department of Clinical Chemistry, Royal
Liverpool University Hospital, The University of Liverpool, UK; ^[2]Human
Bone Cell Research Group, Department of Human Anatomy and Cell
Biology, The University of Liverpool, UK

- 10:24 21 EFFECT OF RECOMBINANT HUMAN RANKL ON FORMATION OF OSTEOCLASTS: CORRELATION BETWEEN RELEASE OF BETA C-TERMINAL TELOPEPTIDES FROM DENTINE DISCS AND AREA OF RESORPTION
B Y Y Chan^[1], K A Buckley^[2], J Dutton^[1], J A Gallagher^[2], W D Fraser^[1].
^[1]Department of Clinical Chemistry, Royal Liverpool University Hospital, The University of Liverpool, UK; ^[2]Human Bone Cell Research Group, Department of Human Anatomy and Cell Biology, The University of Liverpool, UK
- 10:32 22 SERUM OSTEOPROTEGERIN AND SERUM RANKL IN PAGET'S DISEASE
G Martini, R Valenti, S Giovani, L Gennari, S Salvadori, B Galli, D Merlotti, R Nuti. Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Siena, Italy
- 10:40 COFFEE AND POSTERS
- 11:00-12:40 Complications
Chairs: Ken Lyles/Michael Stone
- 11:00 IS12 RHEUMATOLOGICAL COMPLICATIONS OF PAGET'S DISEASE
Phil Helliwell (Leeds, UK)
- 11:20 IS13 HEARING IN PAGET'S DISEASE
Richard Ramsden (Manchester, UK)
- 11:40 IS14 ORTHOPAEDIC COMPLICATIONS OF PAGET'S DISEASE
Jimmy Hutchison (Aberdeen, UK)
- 12:00 Oral communications
Chairs: Ken Lyles/Michael Stone
- 12:00 23 CONCURRENT PAGET'S DISEASE OF BONE AND PRIMARY HYPERPARATHYROIDISM
C Leens, J P Devogelaer. Department of Rheumatology, Saint-Luc University Hospital, Université Catholique de Louvain, B-1200 Brussels, Belgium
- 12:08 24 FOOT PROBLEMS IN PAGET'S DISEASE
A Williams^[1,3], T W O'Neill^[2], S Mercer^[2], C J Nester^[3]. ^[1]Department of Podiatry, University of Salford, UK; ^[2]Department of Rheumatology, Hope Hospital, Salford, UK; ^[3] Centre for Rehabilitation and Human Performance Research, University of Salford, UK

- 12:16 25 HETEROTOPIC BONE FORMATION FOLLOWING HIP ARTHROPLASTY IN PAGET'S DISEASE
N A Athanasou, M Maki, I Itonaga, D Ferguson, E McNally, R Gundle.
Nuffield Department of Orthopaedic Surgery & Clinical Laboratory Sciences, University of Oxford, Oxford, OX3 7LD, UK
- 12:24 26 ACTIONS OF CHEMICALLY MODIFIED TETRACYCLINES ON OSTEOCLAST AND OSTEOBLAST LINEAGE CELLS IN VITRO
S G Holmes, K Still, D J Buttle, N J Bishop, P S Grabowski. Academic Unit of Child Health, University of Sheffield, UK
- 12:32 27 VITAMIN D3 ANTAGONISTS: A POTENTIAL TREATMENT FOR PAGET'S DISEASE
S Ishizuka^[1,2], N Kurihara^[2], Y Harada^[1], K Takenouchi^[1], J Cornish^[3], T Cundy^[3], S V Reddy^[2], G D Roodman^[2,4]. ^[1]Teijin Institute for Bio-Medical Research, Tokyo, Japan; ^[2]University of Pittsburgh Medical Center, USA; ^[3]University of Auckland, New Zealand; ^[4]VA Medical Center, Pittsburgh, USA
- 12:40 LUNCH
- 13:30 Attended posters (even-numbered posters, 2, 4, 6 etc)
- 14:00-17:15 Treatment
Chairs: Jean-Pierre Devogelaer/Richard Eastell
- 14:00 IS15 PRE-CLINICAL EVALUATION OF BISPHTHONATES
Jonathan Green (Basle, Switzerland)
- 14:30 IS16 COMPARISON OF UK AND US PRACTICE AND GUIDELINES
IS17 Peter Selby (Manchester, UK)/Ethel Siris (New York NY, USA)
- 15:10 Oral communications
Chairs: Jean-Pierre Devogelaer/Richard Eastell
- 15:10 28/29 THE PRISM TRIAL: A RANDOMISED TRIAL OF INTENSIVE VS SYMPTOMATIC MANAGEMENT FOR PAGET'S DISEASE OF THE BONE and THE PRISM TRIAL: A DNA REPOSITORY SUB-STUDY
A L Langston^[1], S H Ralston^[2], M K Campbell^[1], W D Fraser^[3], P L Selby^[4] and the PRISM Trial Group. ^[1]Health Services Research Unit, University of Aberdeen, UK; ^[2]University of Aberdeen Medical School, Institute of Medical Sciences, UK; ^[3]Department of Clinical Chemistry, The University of Liverpool, UK; ^[4]University of Manchester Department of Medicine, Manchester Royal Infirmary, UK

- 15:20 30 INTRAVENOUS PAMIDRONATE OR ORAL ALENDRONATE FOR THE TREATMENT OF PAGET'S DISEASE OF BONE: RESULTS OF A RANDOMISED CONTROLLED TRIAL
J P Walsh^[1,4], G O Stewart^[2], R K Will^[3], R A Criddle^[5], R L Prince^[1,4], B G A Stuckey^[1], L C Ward^[1], S S Dhaliwal^[1], P Drury^[7], C I Bhagat^[6], R W Retallack^[1], G N Kent^[6], S Vasikaran^[8], D H Gutteridge^[1].
^[1]Department of Endocrinology & Diabetes, Sir Charles Gairdner Hospital, Nedlands, WA, Australia; ^[2]Department of Endocrinology & Diabetes, Fremantle Hospital, WA, Australia; ^[3]Department of Rheumatology, Royal Perth Hospital, WA, Australia; ^[4]Department of Medicine, University of Western Australia, Australia; ^[5]Department of Rehabilitation & Aged Care, Sir Charles Gairdner Hospital, Nedlands, WA, Australia; ^[6]PathCentre, Nedlands, WA, Australia; ^[7]Department of Radiology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia; ^[8]Department of Biochemistry, Royal Perth Hospital, Australia
- 15:28 31 COMPARISON OF CLINICAL EFFECTS OF ORAL RISEDRONATE AND INTRAVENOUS PAMIDRONATE IN PATIENTS WITH PAGET'S DISEASE OF BONE
S B Seechurn, M Davies, P L Selby. University Department of Medicine, Manchester Royal Infirmary, UK.
- 15:36 32 ZOLEDRONIC ACID IN THE MANAGEMENT OF PAGET'S DISEASE OF BONE
S Harrison, M Davies, P L Selby. University Department of Medicine, Manchester Royal Infirmary, UK
- 15:48 TEA
- 16:15 Treatment controversies
Chairs: Michael Davie/Michael Davies
- 16:15 33 INTRAVENOUS ZOLEDRONIC ACID FOR TREATING INTRACTABLE PAGET'S DISEASE OF BONE
C Moniz, T Mangion, R Chandra. Metabolic Bone Clinic, Clinical Biochemistry, Kings College Hospital, London, UK
- 16:25 34 DO WE GIVE TOO MUCH BISPHOSPHONATE FOR PAGET'S DISEASE OF BONE?
M Davies, P L Selby. University Department of Medicine, Manchester Royal Infirmary, UK
- 16:35 35 RESPONSIVENESS-RESISTANCE- AND RE-RESPONSIVENESS TO PAMIDRONATE IN A PATIENT WITH PAGET'S DISEASE OF THE VERTEBRAL BODY
P Miller. Colorado Center for Bone Research, Colorado, USA

16:45 Clinical problems in Paget's Disease: cases for discussion

Chairs: Michael Davie/Michael Davies

17:15 BREAK

17:30 Keynote lecture

Chairs: Marilyn McCallum/Graham Russell

Sir Julian Paget

18:00 End

19:00 DINNER